Trial Profile

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs P-BCMA-ALLO1 (Primary) ; Cyclophosphamide; Fludarabine; Rimiducid
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Sponsors Poseida Therapeutics

Most Recent Events

12 Nov 2025 Planned End Date changed from 1 Dec 2039 to 1 Mar 2042.
12 Nov 2025 Planned primary completion date changed from 1 Dec 2027 to 1 Mar 2029.
09 Dec 2024 According to Poseida Therapeutics media release, data from this study presented at the 66th ASH Annual Meeting and Exposition being held in San Diego on December 7-10, 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com